Brown Brothers Harriman & Co. Boosts Holdings in Haleon plc (NYSE:HLN)

Brown Brothers Harriman & Co. grew its stake in shares of Haleon plc (NYSE:HLN) by 80.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,653 shares of the company’s stock after buying an additional 6,084 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Haleon were worth $144,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Fortitude Family Office LLC purchased a new stake in shares of Haleon during the 3rd quarter valued at $28,000. Cultivar Capital Inc. purchased a new position in Haleon in the 2nd quarter worth $40,000. Prospera Private Wealth LLC purchased a new position in Haleon in the 3rd quarter worth $57,000. Hexagon Capital Partners LLC raised its position in Haleon by 66.6% in the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock worth $55,000 after purchasing an additional 2,677 shares during the period. Finally, BOKF NA raised its position in Haleon by 68.8% in the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on HLN. Berenberg Bank assumed coverage on shares of Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. The Goldman Sachs Group lowered shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Morgan Stanley raised their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Trading Up 1.4 %

Shares of HLN opened at $9.73 on Thursday. The firm’s 50-day moving average price is $9.97 and its 200-day moving average price is $9.41. The firm has a market capitalization of $44.02 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 2.89 and a beta of 0.30. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.